By
Drug Target Review2025-02-10T08:00:56
UC Davis researchers achieve a breakthrough in synthesising ibogaine, enabling safer drug development for addiction and depression treatment.
Already a member? Sign in
By highlighting cutting-edge research and its practical applications, Drug Target Review enables readers to make decisions that accelerate innovation, translate discoveries into therapies, and create tangible benefits for patients worldwide.
By becoming a member you join a connected and collaborative community driving the industry forward. Member benefits include:
2026-05-12T09:31:00Z
Contributor Sugish Pillai, Axel Ziemke and Dr Gary Kusdian
2023-05-23T11:10:47
Sponsored by NanoTemper Technologies
2025-09-24T14:00:00
Sponsored by Eurofins Discovery
2023-05-31T15:16:10
Sponsored by Bio-Techne
2023-01-19T15:38:17
Sponsored by Cell Signaling Technology
2023-02-16T14:53:10
Sponsored by Cell Signaling Technology
2023-01-05T14:41:33
Sponsored by Cell Signaling Technology
Site powered by Webvision Cloud